A Phase 1 Trial of MLN0128 in Combination With AZD9291 in Advanced EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
This phase I trial studies the side effects and best dose of transducer of regulated CREB
activity 1/2 (TORC1/2) inhibitor INK128 when given together with epidermal growth factor
receptor (EGFR) inhibitor AZD9291in treating patients with advanced EGFR mutation positive
non-small cell lung cancer that has spread to other places in the body (advanced) and has
progressed after treatment with an EGFR tyrosine kinase inhibitor. TORC1/2 inhibitor INK128
and EGFR inhibitor AZD9291 may stop the growth of tumour cells by blocking some of the
enzymes needed for cell growth.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society